Valens: a new name in the vaccine adjuvants market

By SPI Pharma

Adjuvants are often key to improving the immunogenicity of vaccines and companies entering this market must make substantial investments to achieve the necessary scale and quality to compete. World Pharmaceutical Frontiers speaks to excipients specialist SPI Pharma about the launch of its new Valens brand and how it will serve the vaccine, parenteral dosage form, and biologic drug market spaces.

Enter your details below to view the free white paper

By downloading this White Paper, you acknowledge that may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Business Trade Media International Limited may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.